Celsis International plc launched the Celsis ReACT, the first RNA-based assay for detecting objectionable organisms without the need for expensive equipment or specialized training.

Manufacturers of pharmaceutical products using Celsis Rapid Detection systems can utilize this RNA-based assay to obtain a 2-hour result on samples that test positive for microbial contamination. Celsis ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staphylococcus aureus, yeast, and mold, and can be customized for facility-specific or wild-strain organisms.

Celsis customers will be able to use Celsis ReACT following the primary Celsis AKuScreen assay, which detects the presence or absence of microbial organisms in 18 to 24 hours instead of the typical 3 to 5 days for microbial limits testing. The same primary system has also been proven successful in equaling the traditional 14-day sterility test in less than half the time. Following a positive result on the Celsis primary system, the new Celsis ReACT assays use Celsis’ existing instrument platform to provide actionable intelligence and secondary analysis within 2 hours.

Celsis ReACT uses simple protocols with user-friendly, color-coded steps. Basic measuring and pipetting skills are all that’s required technically, and the Celsis system provides clear results in two hours.
www.celsis.com

Published in Drug Discovery & Development magazine: Vol. 12, No. 6, June, 2009, p.34.